Urinary Tract Infections

Urinary Tract Infections (UTIs) are amongst the most prevalent bacterial infections, in the community as well as in the whole health-care system. Antimicrobial resistance of uropathogens is increasing worldwide. For the treatment of complicated UTI and HAUTI however, new antibiotics are urgently needed. Analogues of substances of known antibiotic classes (fluoroquinolones, 3rd gen cephalosporins, betalactamase-inhibitors, monobactams, aminoglycosides, and tetracyclines) are developed further. Compounds directed against novel bacterial targets, such as aminoacyl-tRNA synthetase inhibitors, e.g. mupirocin, LpxC inhibitors, oligonucleotide therapeutics, peptidomimetics are currently investigated. However, new antibiotic substances can only become successful therapeutics for UTI, if they are largely eliminated by the kidneys in its active form. Since bacterial growth and also antibacterial activity are very much depending on the milieu, pharmacokinetic/ pharmacodynamics considerations directed to the urinary tract should be investigated already in phase one studies for better profiling new substances selected for clinical development. Florian ME Wagenlehner, New Treatment Strategies in Urinary Tract Infections

• Share this page
• 
• 
• 
• 
• 
• 

Last date updated on September, 2024